Jefferies London 2026: CRISPR Therapeutics CEO Sam Kulkarni walks us through the company's increasingly advancing pipeline, which includes an siRNA
He discusses ANGPTL3 in cardiology and allo CAR-T, both of which recently had data at medical meedings. Plus the idea behind branching out to siRNA, which targets FXI for thrombotic conditions.
Coverage brought to you by










.png)
